TCTR20211004001已完成不适用
Immunogenicity and safety of an intradermal boost in healthy general population; preliminary study (COVID-19)
faculty of medicine, Prince of songkla university0 个研究点目标入组 240 人开始时间: 2021年10月4日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 60 Years（—）
- 性别
- All
入选标准
- •1. Thai adults aged 18-60 years, who have been completed two-dose regimen of inactive SARS-CoV-2 vaccine in the past 1 - 3 months
- •2. The subjects are able to and willing to comply with the requirements of the clinical trial program and could complete the 3-month follow-up of the study.
- •3. Individuals who are in good health condition at the time of entry into the trial as determined by medical history, physical examination and clinical judgment of the investigator and meet the requirements of immunization
- •4. The subject can provide with informed consent and sign informed consent form (ICF).
排除标准
- •1. Have the medical history or family history of convulsion, epilepsy, encephalopathy and psychosis.
- •2. Be allergic to any component of the research vaccines or used to have a history of hypersensitivity or serious reactions to vaccination.
- •3. Women with positive urine pregnancy test, pregnant or breast-feeding, or have a pregnancy plan within six months of after baseline period.
- •4. Have infectious diseases, including HIV and SARS-CoV-2 infection.
- •5. Have history of SARS-CoV-2 infection
- •6. Have severe chronic diseases or condition in progress cannot be controlled. For examples, poor controlled DM and uncontrolled HT.
- •7. Have the history of urticaria 1 year before receiving the investigational vaccine.
- •8. Have known underlying diseases of thrombocytopenia or other coagulation disorders (which may cause contraindications for intramuscular injection).
- •9. Have needle sickness.
- •10. Have the history of immunosuppressive therapy, cytotoxic therapy or systemic corticosteroids
- •11. Have received blood products within 4 months before injection of investigational vaccines.
- •12. Under anti-tuberculosis treatment.
- •13. Not be able to follow the protocol, or not be able to understand the informed consent according to the researcher's judgment, due to various medical, psychological, social or other conditions.
研究者
相似试验
已完成
2 期
Immunogenicity and safety of intradermal injection of reduced dose Inactivated Poliovirus vaccine (IPV) with a jet injector in healthy adultsinfantile paralysispolio10047438NL-OMON32437ederlands Vaccin Instituut120
进行中（未招募）
不适用
Immunogenicity and safety of intradermal injection of reduced dose Inactivated Poliovirus vaccine (IPV) with a jet injector in healthy adults - Intradermal injection of reduced dose IPV in adultsEUCTR2009-015175-27-NLetherlands Vaccine Institute
已完成
不适用
Onderzoek naar de bijwerkingen en immuunrespons na een boostervaccinatie tegen polio, toegediend met een naaldloze Jet Injector.poliomyelitis, polio, vaccination, vaccinatie, intradermal, intradermaal, jet injector, needle-free, naaldloosNL-OMON26044etherlands Vaccine Institute RIVM, formerly Nederland Vaccine, Institute (NVI)120
招募中
4 期
Intradermal booster COVID-19 vaccinatioIntradermal mRNA-based vaccine following the 2-dose primary series of ChAdOx1 (AstraZeneca) can provide a sufficient level of immunity against SAR-CoV-2booster vaccine, third dose, SAR-CoV2, older adultTCTR20220112002Faculty of Medicine Siriraj Hospital, Mahidol University210
进行中（未招募）
不适用
Study of a Booster Injection of Pentaxim™ Vaccine Administered With Sanofi Pasteur's Dengue Vaccine in Healthy Toddlers Aged 15 to 18 Months in MexicoPrevention of symptomatic dengue diseaseEUCTR2014-001736-11-Outside-EU/EEASanofi Pasteur SA732